Gene Editing to
February 2, 2022
The paper “CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus” was published in iScience.
For more details, please refer the release by the Institute of Medical Science, the University of Tokyo.
January 31, 2022
C4U and Sumitomo Dainippon Pharma have entered into the next stage of the joint research aiming the medical application of CRISPR-Cas3 by specifying the target gene and cell in the field of the central nervous system diseases. This progress has been made based on our joint research which was announced on August 3, 2021.
January 27, 2022
C4U, the Division of Animal Genetics, the Institute of Medical Science, the University of Tokyo and Transgenic Inc. have entered into the joint research agreement for genome editing experiments using mouse model with humanized exon.
January 11, 2022
C4U has been awarded the "JHVS2021 Venture Award" as a result of the "90-second elevator pitch" at the "Japan Healthcare Venture Summit 2021" held on October 13-15, 2021.
Our CEO Hirai will present the award-winning pitch at the JHVS 2021 Symposium to be held on February 3 and 4, 2022. (The pitch will be conducted in Japanese.)
November 8, 2011
C4U and Nippon Gene have entered into a non-exclusive sublicense agreement granting Nippon Gene develop, manufacture and sell reagents utilizing CRISPR-Cas3 technology.